Avalo Therapeutics (AVTX) Total Liabilities (2016 - 2025)
Historic Total Liabilities for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $33.6 million.
- Avalo Therapeutics' Total Liabilities fell 5568.86% to $33.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.6 million, marking a year-over-year decrease of 5568.86%. This contributed to the annual value of $17.7 million for FY2024, which is 2930.09% up from last year.
- Latest data reveals that Avalo Therapeutics reported Total Liabilities of $33.6 million as of Q3 2025, which was down 5568.86% from $22.0 million recorded in Q2 2025.
- Avalo Therapeutics' 5-year Total Liabilities high stood at $224.8 million for Q1 2024, and its period low was $13.7 million during Q4 2023.
- Over the past 5 years, Avalo Therapeutics' median Total Liabilities value was $38.6 million (recorded in 2022), while the average stood at $50.7 million.
- Its Total Liabilities has fluctuated over the past 5 years, first surged by 42894.69% in 2024, then crashed by 9292.39% in 2025.
- Over the past 5 years, Avalo Therapeutics' Total Liabilities (Quarter) stood at $57.1 million in 2021, then fell by 22.49% to $44.3 million in 2022, then crashed by 69.09% to $13.7 million in 2023, then grew by 29.3% to $17.7 million in 2024, then soared by 89.56% to $33.6 million in 2025.
- Its Total Liabilities was $33.6 million in Q3 2025, compared to $22.0 million in Q2 2025 and $15.9 million in Q1 2025.